NEW YORK (GenomeWeb) – The Scottish molecular diagnostics firm DestiNA Genomics has received €1.2 million ($1.5 million) in equity investments that it will use to commercialize novel tests for cancer and infectious diseases, the economic development agency Scottish Enterprise said this week.

The new funding for the Edinburgh-based company was led by Vitro Group of Spain, the Scottish Investment Bank (part of Scottish Enterprise), Old College Capital, and private investors in the UK, Spain, Belgium, and Saudi Arabia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.